Processa Pharmaceuticals, Inc. (PCSA) Income Statement
PCSA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPCSA revenue and net income
PCSA profit margins
PCSA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PCSA quarterly EPS vs estimates
Processa Pharmaceuticals beat the analyst EPS estimate in 4 of the last 7 quarters. Next report: November 5, 2026.
PCSA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $5,000 | $113,425 |
| Cost of revenue | $1,204 | $782 | $222 | $874,013 | $875,349 | $882,062 | $877,897 | $630,092 | $1,381 | $125,876 |
| Gross profit | −$1,204 | −$782 | −$222 | −$874,013 | −$875,349 | −$882,062 | −$877,897 | −$630,092 | −$1,865 | −$12,451 |
| Research & development | $7.8M | $7.3M | $5.8M | $10.7M | $6.9M | $11.1M | $2.3M | $3.1M | $926,117 | $29,246 |
| Sales, general & admin | $6.2M | $4.8M | $5.7M | $8.8M | $4.7M | $3.3M | $1.6M | $1.4M | $876,316 | $945,460 |
| Total operating expenses | $14.0M | $12.1M | $11.5M | $19.4M | $12.1M | $14.3M | $3.9M | $4.5M | $1.8M | $974,706 |
| Operating income | −$14.0M | −$12.1M | −$11.5M | −$20.3M | −$12.1M | −$15.1M | −$3.9M | −$4.5M | −$1.8M | $2.7M |
| Interest income | $109,491 | $201,088 | $326,552 | $101,202 | $11,989 | $3,174 | $11,548 | $18,297 | $5,181 | $0 |
| Interest expense | — | — | — | $101,202 | $362 | $281,122 | $36,658 | $161,205 | $35,693 | $235,644 |
| Income before taxes | −$13.6M | −$11.9M | −$11.1M | −$27.4M | −$12.0M | −$15.4M | −$4.0M | −$4.7M | −$1.9M | −$3.0M |
| Income taxes | — | — | −$2 | $27.4M | −$530,611 | −$1.0M | −$602,716 | −$902,801 | −$18,189 | $100 |
| Net income | −$13.6M | −$11.9M | −$11.1M | −$27.4M | −$11.4M | −$19.0M | −$3.4M | −$3.8M | −$1.9M | −$3.4M |
| EBITDA | −$13.6M | −$11.8M | −$11.1M | −$26.6M | −$10.8M | −$14.3M | −$3.1M | −$3.9M | −$1.8M | −$2.5M |
| EPS (diluted) | −$5.27 | −$79.49 | −$91.88 | −$620.00 | −$265.21 | −$101.73 | −$3.29 | −$14.26 | −$0.37 | −$14.92 |
| Gross margin | — | — | — | — | — | — | — | — | −37.3% | −11.0% |
| Operating margin | — | — | — | — | — | — | — | — | −36,048.7% | 2,372.6% |
| Net margin | — | — | — | — | — | — | — | — | −37,126.3% | −2,957.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $12.5M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $301 | $301 | $301 | $301 | $301 | $301 | $3.4M | $139 | $139 | $140 | $82 |
| Gross profit | — | −$301 | −$301 | −$301 | −$301 | −$301 | −$301 | −$3.4M | −$139 | −$139 | −$140 | −$82 |
| Research & development | $649,877 | $1.8M | $2.1M | $1.7M | $2.4M | $1.6M | $1.7M | $2.3M | $1.7M | $1.5M | $1.3M | $1.2M |
| Sales, general & admin | $1.7M | $1.5M | $1.6M | $1.8M | $1.5M | $1.3M | $1.0M | $1.1M | $1.4M | $1.3M | $1.1M | $1.0M |
| Total operating expenses | $2.3M | $3.3M | $3.7M | $3.5M | $4.0M | $2.8M | $2.7M | $3.4M | $3.1M | $2.8M | $2.5M | $2.2M |
| Operating income | −$2.3M | −$3.3M | −$3.7M | −$3.5M | −$4.0M | −$2.8M | −$2.7M | −$3.4M | −$3.1M | −$2.8M | −$2.5M | −$2.2M |
| Interest income | — | $13,859 | $35,491 | $52,000 | — | $12,585 | $6,023 | $40,150 | — | $83,217 | $64,519 | $85,661 |
| Interest expense | $2,003 | — | — | — | — | — | — | — | — | — | $4.2M | — |
| Income before taxes | −$3.3M | −$3.4M | −$3.4M | −$3.4M | −$3.9M | −$2.8M | −$2.7M | −$3.4M | −$3.0M | −$2.7M | −$2.4M | −$2.1M |
| Income taxes | — | — | — | — | — | — | — | −$203 | $1 | −$139 | $2.0M | $2.2M |
| Net income | −$3.3M | −$3.4M | −$3.4M | −$3.4M | −$3.9M | −$2.8M | −$2.7M | −$3.4M | −$3.0M | −$2.7M | −$2.4M | −$2.1M |
| EBITDA | −$3.3M | −$3.4M | −$3.4M | −$3.4M | −$3.9M | −$2.8M | −$2.7M | −$3.4M | −$3.0M | −$2.7M | −$2.4M | −$2.1M |
| EPS (diluted) | −$1.19 | — | — | −$1.75 | −$0.25 | −$7.50 | −$0.74 | −$25.75 | −$25.25 | −$27.75 | −$1.70 | −$40.00 |
| Gross margin | — | — | — | — | — | — | −0.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −21.9% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −21.9% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PCSA's financial statements (latest annual report filed March 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PCSA financial results
Processa Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $13.6 million. Diluted earnings per share came to −$5.27.
See the PCSA stock overview for the latest quote and news, or the PCSA chart for price history and technical indicators.
PCSA income statement FAQ
Does Processa Pharmaceuticals have revenue?
Processa Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Processa Pharmaceuticals profitable?
No. Processa Pharmaceuticals reported a net loss of $13.6 million in fiscal 2025.
How much does Processa Pharmaceuticals spend on research and development?
Processa Pharmaceuticals spent $7.8 million on research and development in fiscal 2025.
What are Processa Pharmaceuticals's earnings per share?
Processa Pharmaceuticals earned $-5.27 per diluted share in fiscal 2025, compared with $-79.49 a year earlier.
When will Processa Pharmaceuticals report its next earnings?
Processa Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does Processa Pharmaceuticals's fiscal year end?
Processa Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 18, 2026.